Salem Investment Counselors Inc Bristol Myers Squibb CO Transaction History

Salem Investment Counselors Inc

  • $3.24 Billion
  • Q3 2024

A detailed history of Salem Investment Counselors Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Salem Investment Counselors Inc holds 32,313 shares of BMY stock, worth $1.72 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
32,313
Previous 35,514 9.01%
Holding current value
$1.72 Million
Previous $1.47 Million 13.43%
% of portfolio
0.05%
Previous 0.05%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024
SELL
$39.66 - $51.75 $126,951 - $165,651
-3,201 Reduced 9.01%
32,313 $1.67 Million
Q2 2024

Jul 11, 2024
SELL
$40.25 - $52.99 $1.64 Million - $2.16 Million
-40,854 Reduced 53.5%
35,514 $1.47 Million
Q1 2024

Apr 11, 2024
SELL
$47.98 - $54.4 $299,635 - $339,728
-6,245 Reduced 7.56%
76,368 $4.14 Million
Q4 2023

Jan 16, 2024
SELL
$48.48 - $57.85 $974,690 - $1.16 Million
-20,105 Reduced 19.57%
82,613 $4.24 Million
Q3 2023

Oct 04, 2023
SELL
$57.89 - $64.73 $129,036 - $144,283
-2,229 Reduced 2.12%
102,718 $5.96 Million
Q2 2023

Jul 19, 2023
SELL
$63.71 - $70.74 $258,089 - $286,567
-4,051 Reduced 3.72%
104,947 $6.71 Million
Q1 2023

May 11, 2023
BUY
$65.71 - $74.53 $704,016 - $798,514
10,714 Added 10.9%
108,998 $7.55 Million
Q4 2022

Feb 15, 2023
BUY
$68.48 - $81.09 $608,650 - $720,727
8,888 Added 9.94%
98,284 $7.07 Million
Q3 2022

Nov 09, 2022
SELL
$0.13 - $76.84 $0 - $307
-4 Reduced -0.0%
89,396 $6.36 Million
Q2 2022

Aug 17, 2022
BUY
$72.62 - $79.98 $304,132 - $334,956
4,188 Added 4.91%
89,400 $6.93 Million
Q1 2022

May 16, 2022
SELL
$61.48 - $73.72 $823,524 - $987,479
-13,395 Reduced 13.58%
85,212 $6.22 Million
Q4 2021

Feb 15, 2022
BUY
$53.63 - $62.52 $155,687 - $181,495
2,903 Added 3.03%
98,607 $6.15 Million
Q3 2021

Nov 15, 2021
BUY
$59.17 - $69.31 $188,101 - $220,336
3,179 Added 3.44%
95,704 $5.66 Million
Q2 2021

Aug 17, 2021
BUY
$61.91 - $67.42 $1.78 Million - $1.94 Million
28,736 Added 45.05%
92,525 $6.18 Million
Q1 2021

May 17, 2021
BUY
$59.34 - $66.74 $460,359 - $517,768
7,758 Added 13.85%
63,789 $4.03 Million
Q4 2020

Feb 17, 2021
BUY
$57.74 - $65.43 $5,254 - $5,954
91 Added 0.16%
56,031 $3.48 Million
Q3 2020

Nov 13, 2020
BUY
$57.43 - $63.64 $456,855 - $506,256
7,955 Added 16.58%
55,940 $3.37 Million
Q2 2020

Aug 13, 2020
BUY
$54.82 - $64.09 $225,310 - $263,409
4,110 Added 9.37%
47,985 $2.82 Million
Q1 2020

May 14, 2020
BUY
$46.4 - $67.43 $604,870 - $879,017
13,036 Added 42.27%
43,875 $2.45 Million
Q4 2019

Feb 13, 2020
SELL
$49.21 - $64.19 $42,714 - $55,716
-868 Reduced 2.74%
30,839 $1.98 Million
Q3 2019

Nov 13, 2019
SELL
$42.77 - $50.71 $1.25 Million - $1.48 Million
-29,169 Reduced 47.92%
31,707 $1.61 Million
Q2 2019

Aug 14, 2019
SELL
$44.62 - $49.34 $1.15 Million - $1.27 Million
-25,671 Reduced 29.66%
60,876 $2.76 Million
Q1 2019

May 15, 2019
BUY
$45.12 - $53.8 $202,272 - $241,185
4,483 Added 5.46%
86,547 $5.37 Million
Q4 2018

Feb 15, 2019
SELL
$48.76 - $63.23 $218,591 - $283,460
-4,483 Reduced 5.18%
82,064 $4.27 Million
Q3 2018

Nov 14, 2018
SELL
$55.19 - $62.25 $85,986 - $96,985
-1,558 Reduced 1.77%
86,547 $5.37 Million
Q2 2018

Aug 15, 2018
SELL
$50.53 - $62.98 $692,463 - $863,077
-13,704 Reduced 13.46%
88,105 $4.88 Million
Q1 2018

May 15, 2018
SELL
$59.92 - $68.98 $162,263 - $186,797
-2,708 Reduced 2.59%
101,809 $6.28 Million
Q4 2017

Feb 16, 2018
BUY
$59.94 - $65.35 $120,299 - $131,157
2,007 Added 1.96%
104,517 $6.41 Million
Q3 2017

Nov 16, 2017
BUY
$55.23 - $63.74 $5.66 Million - $6.53 Million
102,510
102,510 $6.63 Million

Others Institutions Holding BMY

# of Institutions
2,428
Shares Held
1.5B
Call Options Held
29.7M
Put Options Held
32.2M
View Full List

About BRISTOL MYERS SQUIBB CO

BMY Quotes by TradingView
  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Salem Investment Counselors Inc Portfolio

Follow Salem Investment Counselors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Salem Investment Counselors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Salem Investment Counselors Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email